Intra-Cellular Therapies, Inc.
NOVEL USES
Last updated:
Abstract:
The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
Status:
Application
Type:
Utility
Filling date:
20 May 2020
Issue date:
3 Dec 2020